Jiangsu Huanghe Pharmaceutical Co., Ltd. is located at No. 8 Huanghe Road, Funing Economic Development Zone. It was founded in 1970. The predecessor was the local state-owned Funing County Pharmaceutical Factory of Jiangsu Province (later renamed Yancheng Fourth Pharmaceutical Factory), in 1999 Acquired by Huanghe Group to form Jiangsu Huanghe Pharmaceutical Co., Ltd. The company covers an area of ??135,000 square meters, with a construction area of ??25,000 square meters, a registered capital of 55.07 million yuan, and nearly 350 employees. On May 18, 2014, Huanghe Assets and Wanbang Pharmaceutical reached an equity strategic cooperation, and Huanghe Pharmaceutical became a new member of Wanbang Group. All production lines have passed GMP certification. It is a "national high-tech enterprise", a provincial-level "enterprise technology center", "100 innovative and growing enterprises in Jiangsu Province", a "safety standardization level two" enterprise, and a municipal-level "occupational hygiene demonstration enterprise".
The company has the vision to create a "first-class enterprise featuring characteristic Chinese patent medicines and brand OTC", and the mission of "We promise health with our heart". According to the company's 2017-2021 development strategy, with characteristic Chinese patent medicines, branded OTC varieties and continuous new product listings, the company will achieve sales of nearly 700 million yuan in 2021 and generate profits and taxes of nearly 200 million yuan.
We always insist on and attach importance to product research and development. In recent years, it has cooperated with scientific research institutions and universities such as Xinjiang Institute of Physics and Chemistry of Chinese Academy of Sciences, Jiangxi University of Traditional Chinese Medicine, Nanjing University of Traditional Chinese Medicine and other scientific research institutions for long-term cooperation in the upgrading and improvement of characteristic Chinese patent medicines, research and development of new medicines, research and exploration of cutting-edge medical technology, and brand OTC construction Special laboratories have been established in various fields, and a number of invention patents and major scientific and technological achievements have been obtained.
On February 13, 2018, the CFDA released a list of products that passed the consistency evaluation. The Shilida® (amlodipine besylate tablets) of Jiangsu Huanghe Pharmaceutical Co., Ltd. successfully became the ammonium besylate that passed the consistency evaluation of generic drugs. Clodipine. As of May 15, 2018, there are 31 drug product regulations nationwide, and 24 varieties have passed the consistency evaluation. Stable blood pressure reduction within 24 hours, reducing the risk of stroke and coronary heart disease, this is the core advantage of amlodipine. Amlodipine is the most popular antihypertensive drug in China and is widely used by Chinese patients.
Among the company’s key products, "Dunye Guanxinning Tablets" is a domestic traditional Chinese medicine protected variety. It is a good medicine for the treatment of coronary heart disease, angina pectoris and lipid-lowering, and is a national medical insurance product. The "Compound Yizhi Artemisia Tablet", which is cooperating with the Xinjiang Institute of Physics and Chemistry of the Chinese Academy of Sciences, is a medicine for ethnic minorities. It is mainly used for anti-viral infections and is a brand OTC product; the liver-healing medicine "Shenqi Gankang Tablets" has unique curative effect and ranks among the best in the market share of the same variety; "Hulisan Tablets" for internal and external use is a classic treatment of traumatic injuries A good recipe, it has become the wound treatment choice for the wounded during the war; the century-old classic "piperazine phosphate pagoda sugar" is an OTC product with no side effects and is the choice for children to treat insects. "Simvastatin", "Loratadine Tablets" and other varieties are undergoing generic drug quality and efficacy consistency evaluation, and are expected to become the top three in the country; "Rosiglitazone Hydrochloride Capsules", "Finasteride Tablets", etc. Seventeen products were rated as high-tech products of Jiangsu Province.
Huanghe Pharmaceutical is committed to developing into a "first-class enterprise featuring characteristic Chinese patent medicines and brand OTC", adheres to the corporate culture of "family, school, army" and "professionalism, responsibility, and self-motivated", bringing together various professions Talents, committed to providing safe and effective products for the society.